Literature DB >> 19561868

Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor.

Younos Abdulsattar1, Rahul Bhambri, Anna Nogid.   

Abstract

Entities:  

Year:  2009        PMID： 19561868      PMCID： PMC2697099     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  18 in total

1.  A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.

Authors:  Bengt I Eriksson; Lars C Borris; Ola E Dahl; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Eva Muehlhofer; Christoph Dierig; Frank Misselwitz; Peter Kälebo
Journal:  Circulation       Date:  2006-11-20       Impact factor: 29.690

2.  Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.

Authors:  Ajay K Kakkar; Benjamin Brenner; Ola E Dahl; Bengt I Eriksson; Patrick Mouret; Jim Muntz; Andrea G Soglian; Akos F Pap; Frank Misselwitz; Sylvia Haas
Journal:  Lancet       Date:  2008-06-24       Impact factor: 79.321

3.  Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.

Authors:  Dagmar Kubitza; Michael Becka; Wolfgang Mueck; Michael Zuehlsdorf
Journal:  J Clin Pharmacol       Date:  2006-09       Impact factor: 3.126

4.  Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.

Authors:  Bengt I Eriksson; Lars C Borris; Ola E Dahl; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Frank Misselwitz; Eva Muehlhofer; Peter Kälebo
Journal:  Thromb Res       Date:  2007-02-12       Impact factor: 3.944

Review 5.  Rivaroxaban: a novel, oral, direct factor Xa inhibitor.

Authors:  Paris J Abrams; Christopher R Emerson
Journal:  Pharmacotherapy       Date:  2009-02       Impact factor: 4.705

Review 6.  Rivaroxaban: an oral direct inhibitor of factor Xa.

Authors:  Michael P Gulseth; Jessica Michaud; Edith A Nutescu
Journal:  Am J Health Syst Pharm       Date:  2008-08-15       Impact factor: 2.637

7.  Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.

Authors:  Wolfgang Mueck; Lars C Borris; Ola E Dahl; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Peter Kälebo; Eva Muelhofer; Frank Misselwitz; Bengt I Eriksson
Journal:  Thromb Haemost       Date:  2008-09       Impact factor: 5.249

8.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

9.  Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Hirsh; Kenneth A Bauer; Maria B Donati; Michael Gould; Meyer M Samama; Jeffrey I Weitz
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

10.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Ansell; Jack Hirsh; Elaine Hylek; Alan Jacobson; Mark Crowther; Gualtiero Palareti
Journal:  Chest       Date:  2008-06       Impact factor: 9.410
View more
  7 in total

1.  New options in anticoagulation for the prevention of venous thromboembolism and stroke.

Authors:  Lisa R Clayville; Katherine Vogel Anderson; Shannon A Miller; Erin L St Onge
Journal:  P T       Date:  2011-02

2.  Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial.

Authors:  Kanjana S Perera; Kelvin K H Ng; Sumiti Nayar; Luciana Catanese; Leanne Dyal; Mukul Sharma; Stuart J Connolly; Salim Yusuf; Jackie Bosch; John W Eikelboom; Robert G Hart
Journal:  JAMA Neurol       Date:  2020-01-01       Impact factor: 18.302

3.  Application of Molecular Modeling to Development of New Factor Xa Inhibitors.

Authors:  Vladimir B Sulimov; Irina V Gribkova; Maria P Kochugaeva; Ekaterina V Katkova; Alexey V Sulimov; Danil C Kutov; Khidmet S Shikhaliev; Svetlana M Medvedeva; Michael Yu Krysin; Elena I Sinauridze; Fazoil I Ataullakhanov
Journal:  Biomed Res Int       Date:  2015-09-21       Impact factor: 3.411

4.  Anticoagulant effect and safety assessment of an aqueous extract of Pseudocedrela kotschyi (Schweinf.) harms and Adenia cissampeloides (Planch. Ex Hook.) harms.

Authors:  Wilson Bright Nyansah; George Asumeng Koffuor; Frederick Asare; Linda Gyanfosu
Journal:  J Intercult Ethnopharmacol       Date:  2016-03-30

5.  Optimal release timing of temporary drain clamping after total knee arthroplasty.

Authors:  Yoon Sang Jeon; Jun Sung Park; Myung Ku Kim
Journal:  J Orthop Surg Res       Date:  2017-03-21       Impact factor: 2.359

Review 6.  Potential clinical applications of phytopharmaceuticals for the in-patient management of coagulopathies in COVID-19.

Authors:  Ashis K Mukherjee; Dhruba J Chattopadhyay
Journal:  Phytother Res       Date:  2022-02-11       Impact factor: 6.388

Review 7.  Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.

Authors:  Kavitha Vimalesvaran; Seth J Dockrill; Diana A Gorog
Journal:  Vasc Health Risk Manag       Date:  2018-01-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.